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Abstract 
Background: The aim of this study was to compare the days of hospitalization length between patients treated with 
Moxifloxacin with that of patients treated with a Clindamycin/Ceftriaxone combination and additionally, to isolate 
and identify the oral pathogens involved in orofacial odontogenic infections.
Material and Methods: A pilot-controlled-clinical-trial was carried out on hospitalized patients with cervicofacial 
odontogenic abscesses or cellulitis, who were randomly asigned to two study groups: 1) patients who received 
Moxifloxacin, and 2) patients receiving Clindamycin/Ceftriaxone combination. Infiltrate samples were collected 
through transdermic or transmucosal punction and later cultured on a media specific for aerobic and anaerobic 
microorganisms. Mean hospitalization duration in days until hospital discharge and susceptibility assessment in 
rates were established. 
Results: Mean hospitalization time in days of patients treated with Moxifloxacin was 7.0 ± 1.6 days, while in the 
Clindamycin/Ceftriaxone group, this was 8.4 ± 1.8 days, although significant difference could not be demonstrated 
(p=0.074). A total of 43 strains were isolated, all of these Gram-positive. These strains appeared to be highly sen-
sitive to Moxifloxacin (97.5%) and Ceftriaxone (92.5%). 
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Introduction
Odontogenic infections are bacterial and inflammatory 
diseases that have affected human beings for centuries. 
They are the result of teeth with necrotic pulp tissue due 
to a periapical or periodontal lesion, pericoronal swe-
lling, postsurgical infections, and direct trauma resulting 
in epithelial breach (1); they start as localized infections, 
but when these infectious processes are not well con-
trolled, they can invade surrounding subcutaneous (s.c.) 
tissues, alveolar bone, and periostium via the periodontal 
margin and cause submucosal infiltrates and abscesses 
or cellulitis (2,3). These odontogenic infections can even 
penetrate into deep planes and aponeurotic spaces, which 
are ineffective anatomical barriers to the spread of infec-
tion, through the orofacial, intracraneal, mediastinal, and 
neck regions, producing serious, life-threatening septic 
complications, such as airway compromise, involvement 
of major blood vessels, bacterial endocarditis, pulmonary 
infections, cervical necrotizing fasciitis, necrotizing me-
diastinitis, up to retropharyngeal, orbital, and brain abs-
cesses. Prognosis depends on the patient’s immunocom-
petence and the site of the inflammatory process (1,4). 
These are usually polymicrobial infections in nature, such 
as mixed aerobe/facultative anaerobe infections, and pre-
dominantly constituted by streptococci (5,6).
It has been established that management for odontogenic 
orofacial and neck infections is based on the surgical re-
lief of purulence (6). However, antibiotics are an impor-
tant adjunct during treatment of the infection, especially 
when the patient exhibits signs or symptoms of systemic 
involvement (3). Antimicrobial drug selection for odon-
togenic infections is mainly empirical and is based on 
its clinical effectiveness, minimal side effects, low costs, 
patient tolerability, and ready availability (3,7). Penici-
llin, Amoxicillin/clavulanic acid, and Clindamycin are 
some of the most widely used drugs, despite reports of 
allergic reactions, increasing resistance of microorga-
nisms isolated from odontogenic abscesses or cellulitis, 
and other diverse systemic adverse reactions (8). In addi-
tion, Erythromycin, Tetracycline, and Levofloxacin have 
not proven very effective (7,9). Thus, other alternative 
antimicrobial agents for treating orofacial odontogenic 
infections are desirable.
Moxifloxacin is a tolerable, new, broad-spectrum 8-me-
thoxy quinolone, with good oral-tissue penetration, 
bioavailability, and adequate resorption time after oral 
dosage, as demonstrated in animal models. It offers pro-
mising in vitro and clinical activity against odontogenic 
Conclusions: Moxifloxacin and Ceftriaxone appear to be potential convenient and rational alternatives to traditional 
antibiotics, for treating severe odontogenic infections, in conjunction with surgical extraoral incision, debridement, 
and drainage.
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Gram-negative and multiresistant Gram-positive bacte-
ria, aerobic and anaerobic bacteria, and atypical micro-
organisms, which is comparable to that of Amoxicillin/
clavulanic acid (10-12). On the other hand, Ceftriaxone 
is a new, third-generation, semisynthetic cephalosporin 
with a long half-life that has resulted in the recommen-
dation of the once-daily recommended, IV or intramus-
cularly (IM), administration schedule. It possesses a 
broad spectrum of activity against Gram-positive and 
-negative aerobic bacteria and some anaerobic bacteria. 
Ceftriaxone has been encouragingly effective in com-
plicated and uncomplicated ear, nose, throat, skin, soft 
tissue, bone, and joint infections, with an apparent lack 
of serious side effects (13). In orofacial surgery, Cef-
triaxone is often employed because it achieves high con-
centrations in bone and has shown to be an efficacious 
and cost-effective antimicrobial alternative to Penicillin 
G (IV) for mandible compound fracture antibiotic pro-
phylaxis (14).
Considering the promising antimicrobial properties of 
Moxifloxacin and Ceftriaxone in orofacial surgery, with 
that Clindamycin still widely employed in the manage-
ment of severe odontogenic infections, the aims of this 
preliminary clinical, controlled, and randomized trial 
were to: 1) compare the average duration in days of hos-
pitalization length between patients treated with Moxi-
floxacin with those of patients treated with a Clindamy-
cin/Ceftriaxone combination; 2) isolate and identify the 
oral pathogens involved in orofacial odontogenic infec-
tions; and 3) compare the efficacy and tolerability of 
Moxifloxacin with those of a Ceftriaxone/Clindamycin 
combination, administered as part of the management of 
orofacial odontogenic abscesses or cellulitis, in a Mexi-
can hospitalized-patient sample. 
Material and Methods
-Patients
Hospitalized patients with severe orofacial odontogenic 
abscesses or cellulitis who required surgical and antimi-
crobial management were enrolled in the present study. 
Inclusion criteria were as follows: >18 years of age; 
good general status (American Society of Anesthesio-
logists [ASA] I or II); body temperature >38.5°C, pain 
(during swallowing or palpation); general involvement; 
trismus, and leukocytosis. Exclusion criteria were as fo-
llows: antimicrobial treatment prior to sample collection; 
pregnant or lactating patients; previous hypersensitivity 
or known adverse reactions to studied antibiotics; addic-
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tion to drugs, and immunosuppressive therapy (steroids, 
chemotherapy) within last 3 months.
-Study design
This was a preliminary, monocentric, two-armed, con-
trolled, unblinded clinical trial carried out following the 
guidelines suggested by the Consolidated Standards of 
Reporting Trials (CONSORT) group for planning and 
reporting clinical trials (Fig. 1) that was performed at the 
Orofacial Surgery Department of the Ignacio Morones 
Prieto Hospital in the city of San Luis Potosi, Mexico. 
The study was conducted in accordance with the De-
claration of Helsinki and was approved by the hospital 
Ethics Committee. All of the subjects signed institutio-
nally approved consent forms. 

Fig. 1. Description of study patient evolution according to Consolidated Standards of Reporting Trials 
(CONSORT) criteria.
Initially and prior to beginning the treatment, baseline 
data, such as medical history and demographic informa-
tion, were collected. Diagnostic tests and clinical and 
radiographic signs and symptoms (e.g., pain intensity, 
percussion, palpation, oral temperature, mouth opening, 
and the presence of lymphadenitis, swelling, erythema, 
or purulent secretion) were performed and assessed, in 
addition to drawing blood samples to measure basic labo-
ratory parameters (blood biometry, blood chemistry, and 
blood clotting tests) (15). Thereafter, microbial sample 
collections and assigned treatments were conducted. 
-Randomization
After obtaining the signed, informed-consent forms, the 
patients were randomly assigned to either study group 
for receiving the corresponding antimicrobial therapy, 
following the permuted-blocks randomization scheme: 
A, the Experimental group, and B, the Control group, 
in six different combinations of four-letter blocks. This 
method can ensure the approximate balance at end of 
recruitment, minimize the chance of imbalance due to 
unexpected shortfall in enrollment, and facilitate plan-
ning and implementation of the treatment administration 
process (16).
-Interventions
The antimicrobial therapy was as follows: experimental 
group, Moxifloxacin, 400 mg IV once daily until infec-
tion remission, and control group, Clindamycin 600 mg 
IV every 6 h plus Ceftriaxone 1 g IV two times daily, 
until infection remission. Before starting antimicrobial 
therapy and following careful skin disinfection with 1% 
povidone-iodine solution, an extraoral incision, tissue 
debridement, drainage placement, and microbiological 
sampling were performed. Concomitantly with the study 
drugs, patients could receive additional medical therapy, 
such as standardized analgesia, dental extractions, or su-
pporting local procedures.
-Microbiological sampling and testing
Abscess samples were obtained through transdermal or 
transmucosal punction, employing a sterilized 10-mL 
hypodermic syringe, under a standard aseptic technique. 
Samples were immediately placed into anaerobe media, 
constituted of prereduced thioglycollate broth enriched 
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with hemin and Menadione, and later incubated in an 
anaerobic atmosphere for 2-4 days. Then, all bacterial 
isolates were cultured on plates with anaerobic CDC agar 
added with 5% sheep blood for 3-5 days at a temperature 
of 37 ± 2°C, followed by their identification to the spe-
cies level through colony characteristics, Gram staining, 
and employing the API 20 A, API 20 Strep, and API 20 
Staph systems (bioMérieux, Durham, NC, USA). Anti-
biotic susceptibility and resistance testing of the isola-
tes to assess antimicrobial agents was performed by the 
modified Kirby-Bauer method (17); microbial inhibition 
zones were measured and classified at three levels: re-
sistant; intermediately sensitive, and highly sensitive, 
according to Clinical & Laboratory Standards Institute 
(CLSI) standards (18).
-Clinical efficacy assessment
Primary clinical outcome of this investigation was ave-
rage duration in days, that is, from study entry until cli-
nical remission of the infectious process (hospital dis-
charge). This outcome was defined by the simultaneous 
occurrence of the following: body temperature <38.5°C; 
no palpatory pain; mouth opening similar or better than 
that at pretreatment, and normal white blood cell count. 
These criteria were evaluated daily. Mouth opening was 
measured as incisal edge distance in mm.
-Statistical analysis
Statistical analysis was initially performed at a descrip-
tive level in terms of the demographic characteristics of 
the patient sample. After this, hypothesis tests were ca-
rried out to determine the differences between means in 
hospitalization-time length in days in both study groups, 
using the non-parametric Kruskal-Wallis test. Antimi-
crobial sensitivity was measured as rates, and the signi-
ficance of the difference between rates was established 
through the goodness-of-fit Chi-square test. In both tests, 
the level of significance was established at 0.05.
Results
A total of 21 patients were enrolled in the present clini-
cal trial (52% female and 48% male), with an age rank 
of 20-69 years (mean age, 41.9 ± 8.3 years). At study 
initiation, 71.4% of patients exhibited a clinical abscess, 
while 28.6% were at cellulitis phase, with an evolution 
period with pain ranking between 2 and 15 days, and 
submandibular and buccal were the most affected apo-
neurotic spaces, in nearly 60% of cases. Odontogenic 
infections were more commonly caused by necrotic tee-
th localized in the mandible (53.8%) than in the maxilla 
(46.2%). Although two patients, one per study group, 
exhibited complications related with an infectious pro-
cess (necrotizing fasciitis and mediastinitis with airway 
compromise, both mild) during the treatment period, all 
patients were successfully managed. No adverse events 
related with study antibiotics were reported in any study 
group.
Mean hospitalization time in the Moxifloxacin group 
was 7.0 ± 1.6 days, and in the control group, 8.4 ± 1.8 
days, implicating no significant statistical difference bet-
ween them (p = 0.074).
On the other hand, 43 bacterial strains were isolated in 
total, with a mean of 2.04 isolates per patient, with the 
predominance of facultative and moderate anaerobe mi-
croorganisms, such as streptococci (23.1%), aerococci 
(20.8%), and staphylococci (11.5%); Candida spp. was 
detected in one case. All isolated microorganisms were 
classified as Gram-positive (Table 1).
After obtaining a sufficient microbial growth, suscepti-
bility tests showed that Moxifloxacin and Ceftriaxone 
exhibited significantly better results than Clindamycin 
(Table 2).
Discussion
In recent years, diverse new antibiotics have been develo-
ped, but none have demonstrated better efficacy or benefit 
in order to replace the use of Penicillin for the treatment 
of these infectious processes. The judicious decision 
to employ a specific antibiotic agent when managing a 
severe odontogenic infection should be based on seve-
ral factors; undoubtedly, the precise clinical diagnosis 
and the etiology are the most important of these factors 
(1,8). In addition, the clinician must collect information 
concerning host-defense mechanisms, infection severity 
and extension, and expected casual pathogens (7). The 
microbial susceptibility data are also crucial, but it may 
take several days for these to be obtained; thus, a prag-
matic, rational approach to empirical antibiotic selection 
is currently acceptable, provided the antibiotic choice is 
based on scientific data and contemporary experience in 
managing orofacial infections (19).
According to the results generated in the present study, 
there were three main findings: a) in all cases, both an-
tibiotic schemes were equally effective in a relatively 
short time for resolution of odontogenic infections; b) 
moderate anaerobic and facultative anaerobic flora was 
mainly found in the microbiologic samples from these 
odontogenic infections, and, c) the microorganisms iso-
lated were significantly less resistant to Moxifloxacin 
and Ceftriaxone with respect to Clindamycin. In addi-
tion, we should mention that all study antibiotics were 
well tolerated, considering that there was no any adverse 
effect related with them.
According to Swift et al. (7) the average time-period 
length for odontogenic infection treatment until remis-
sion is between 5 and 7 days, similar to that in the pre-
sent study; another study was carried out in a Finnish 
sample of 35 patients under hospital care, with a similar 
mean age to ours, of which 25 exhibited local abscesses 
and cellulitis formations without systemic complica-
tions. Mean length of hospital stay was 8.0 days (range, 
2-34 days), equivalent to the value observed here (20). 
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Strain Species Freq. %
Streptococcus intermedius
anginosus
mitis
agalactiae
constellatus
sanguis
pneumoniae
1
1
1
1
4
1
1
2.3
2.3
2.3
2.3
9.3
2.3
2.3
Staphylococcus saccharolyticus
epidermidis
aureus
2
2
1
4.6
4.6
2.3
Aerococcus urinae
viridans
viridans 2
spp
5
1
2
1
11.6
2.3
4.6
2.3
Lactobacillus acidophilus/
jensenii
3 6.9
Eggerthella lenta 3 6.9
Listeria monocytogenes 1 2.3
Propinibacterium granulosum 1 2.3
Lactococcus lactissppcremoris
lactisspplactis
2
1
4.6
2.3
Bifidobacterium spp 2 1 2.3
Peptostreptococcus micros 2 4.6
Leuconostoc spp 1 2.3
Candida spp 1 2.3
Not identified Gram + bacilli 3 6.9
Table 1. Frequency (Freq.) and rate of isolated and identified anaero-
bic microorganisms.
Susceptibility rate (%) Moxifloxacin Ceftriaxone Clindamycin
Resistant 2.5 2.5 22.5
Intermediately sensitive 0 5 12.5
Highly sensitive 92.5 92.5 65
Table 2. Microbial susceptibility rates. Isolated bacteria exhibited significantly higher 
susceptibility (and lower resistance) to Moxifloxacin and Ceftriaxone with respect to 
Clindamycin (p<0.01). Between these two antibiotics, there was not a significant difer-
ence (p = 0.08).
In addition to being cost-effective, especially for hospi-
talized patients, the relatively short therapy-time length 
with Moxifloxacin and Ceftriaxone decreases the risk of 
microbial development of resistance and enables patients 
to return to work earlier. Moxifloxacin and Ceftriaxone 
possess the advantage of being administered only once 
daily, thus enhancing patient compliance, unlike other 
antibiotic schemes that comprise several takes during the 
day; additionally, the lower daily doses of Moxifloxacin 
(400 mg) and ceftriaxone (1 g), in comparison with tho-
se of Clindamycin (2,400 mg) reduce the metabolic load 
in the patients affected (12).
Odontogenic infection is the product of the interdepen-
dent and synergistic metabolism of the diverse pathogenic 
microorganisms involved: individual members within a 
group generate metabolites that are essential for an appro-
priate growth environment of other microorganisms in the 
group, including favorable pH and available nutrients and 
oxygen levels (1,7,8). Our observations are in agreement 
with the findings of previous studies, in which the num-
ber of microbial isolates per patient ranged from 2-5 (9). 
Those studies also reported a polymicrobial constituted of 
anaerobic and facultative anaerobic bacterial flora; howe-
ver, our samples nearly exclusively comprised Gram-
positive facultative anaerobic microorganisms, mainly 
streptococci, aerococci, and staphylococci, and including 
only a few anaerobic species, which could explain the 
excellent antimicrobial activity exhibited by Moxifloxa-
cin and Ceftriaxone (5); our findings are similar to those 
reported by Singh et al. (1) According to Walia et al. (3) 
staphylococci are frequently associated with odontogenic 
abscess formation and typically produce the enzyme coa-
gulase, which cause fibrin deposition in citrated or oxa-
lated blood; on the other hand, streptococci also produce 
enzymes such as streptokinase (fibrinolysin), hylouroni-
daze, and streptodornase, breaking down fibrin, connecti-
ve-tissue ground substance, and lysing cellular debris. All 
of these facts render the rapid spread of infectious micro-
bes into deeper planes (3,8).
Moxifloxacin, but especially Ceftriaxone, have been 
scarcely studied in cases of severe odontogenic infec-
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tions, in which facultative anaerobic and anaerobic mi-
croorganisms are thought to play a central role. Moxi-
floxacin antimicrobial activity depends on the inhibition 
of DNA gyrase and on its well-documented good pene-
tration into spongy and compact bone and muscle tis-
sues; it has shown a minimal inhibitory concentration 
required to inhibit the growth of 90% of organisms 
(MIC90) of between 0.064 to 0.5 mg/l against Viridans 
streptococci, (2,11) achieving good odontogenic-site 
concentrations and exceeding the plasma concentrations 
(2,4). On the other hand, Ceftriaxone possesses bacteri-
cidal activity against group A and group B streptococci 
and peptostreptococcus, and slightly lower action than 
that of Penicillin against Gram-positive cocci, all of 
these pathogen components isolated from odontogenic 
infectious processes; this antimicrobial agent acts by 
inhibiting cell-wall synthesis and possesses a MIC90 
of 0.125 mg/l against isolated streptococci (11,14). As 
demonstrated here and in previous studies, and due to 
their adequate pharmacokinetic properties, both antimi-
crobial agents exhibit excellent tolerability, long half-
life, and high bioavailability for their employment in the 
treatment of odontogenic cervicofacial infections (2,4).
Our results concerning Moxifloxacin and Clindamycin 
resistance are according to those of Warnke et al. (21) 
and Sobottka et al. (4) with nearly 100% of all anaerobe/
facultative anaerobe isolates susceptible to Moxifloxa-
cin, whereas 65% of these were susceptible to Clin-
damicyn. Compared with Penicillin, Tomás et al. (11) 
reported, from a study in which bacteria were isolated 
from blood following dental extractions, that >10% of 
the streptococci were resistant to this antibiotic, whereas 
>20% were resistant to Clyndamycin, and no bacteria 
isolates were resistant to Moxifloxacin. All of these data 
demonstrate the very high susceptibility to Moxifloxacin 
of pathogen microorganisms isolated from severe orofa-
cial, odontogenic infectious processes. 
Moxifloxacin and Ceftriaxone appear to be potential con-
venient and rational alternatives to traditional antibiotics, 
for treating severe odontogenic infections, in conjunction 
with surgical extraoral incision, debridement, and drainage. 
New studies should consider a larger number of patients, in 
order to evaluate if the observed trend is significant.
In conclusion, there were three main findings: a) in all 
cases, both antibiotic schemes were equally effective in 
a relatively short time for resolution of odontogenic in-
fections; b) moderate anaerobic and facultative anaerobic 
flora was mainly found in the microbiologic samples from 
these odontogenic infections, and, c) the microorganisms 
isolated were significantly less resistant to Moxifloxacin 
and Ceftriaxone with respect to Clindamycin.
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